# Dementia awareness month

What are the characteristics and outcomes of patients with dementia admitted to NHS hospitals in England?

Methodology

- Data was extracted from Hospital Episode Statistics for the financial years 2019-2024.
- People with a diagnosis of dementia were included.
- Patients were described by age group and biological sex.
- The diagnosis on admission were recorded.
- The number of deaths were recorded.
- The number of days from first hospital admission with a diagnosis of dementia recorded to death were recorded for patients who died in hospital.

Evidera | PPD COREVITAS

Part of **Thermo Fisher Scientific**

Annual admissions to hospitals in England for people with dementia

Financial Year

Admissions to hospitals have not returned to pre-COVID levels for people with dementia.

Age on admission

Admission to hospital with admission largely affects the older population older than 70.

Common diagnosis

Respiratory related conditions dominate for the reason of admission accompanying dementia.

Evidera | PPD | COREVITAS

Part of **Thermo Fisher Scientific**

Overall mortality and time to mortality

- There were 602,650 persons admitted with a diagnosis of dementia over the 5 years of data.

- 139,562 persons had a death recorded in hospital.

- The median time (midpoint number of days) from the first admission with a diagnosis of dementia to death, in those people who died was 35 days.

- The mean time (all days divided by number of deaths) was 219 days.

About us

CorEvitas and Evidera are part of the PPD clinical research business of Thermo Fisher Scientific. Their solutions include the science-led, regulatory-grade data, evidence-based solutions, strategic consulting, and clinical insights needed to demonstrate the real-world safety, effectiveness, and value of biopharmaceutical and biotechnology products.

Part of **Thermo Fisher Scientific**